We are live on ! Find out more
KALA icon

KALA BIO

45 hedge funds and large institutions have $79.5M invested in KALA BIO in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

2% less funds holding

Funds holding: 46 → 45 (-1)

3.38% less ownership

Funds ownership: 50.01% → 46.63% (-3.4%)

47% less capital inflows, than outflows

Capital inflows: $7.51M | Capital outflows: $14.1M

57% less call options, than puts

Call options by funds: $388K | Put options by funds: $907K

Holders
45
Holders Change
-1
Holders Change %
-2.17%
% of All Funds
0.79%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
6
Reduced
4
Closed
11
Calls
$388K
Puts
$907K
Net Calls
-$519K
Net Calls Change
-$1.5M

KALA Hedge Fund Activity: Q3 2021 in Review

45 of the 5,732 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q3 2021, worth a combined $79.5M — down 54% from $171M a quarter earlier.

Fund positioning in KALA was balanced in Q3 2021: 11 funds opened new positions, 11 closed out, 6 added to existing stakes and 4 trimmed.

The largest buyer was State Street, adding an estimated $1.04M. The largest seller was OrbiMed, cutting an estimated $6.99M.

  • 45 institutional investors held KALA BIO (KALA) as of Q3 2021, down from 46 in Q2 2021.
  • Funds reported $79.5M of KALA BIO stock for Q3 2021, down 54% quarter-over-quarter.
  • 11 funds opened new KALA BIO positions in Q3 2021 and 11 closed out, a net change of 0 holders.
  • The largest KALA BIO buyer in Q3 2021 was State Street, an estimated $1.04M added.
  • The largest KALA BIO seller in Q3 2021 was OrbiMed, an estimated $6.99M sold.

Based on aggregated 13F filings for Q3 2021.